Plain-English translation of NCT07102394 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a medication called —a specially engineered virus—to see if it can safely treat cutaneous neurofibromas, which are small skin tumors that grow in people with neurofibromatosis type 1 (NF1). The medication is injected directly into the tumors, and researchers want to understand how well it works and how your body tolerates it. This is an early-stage study with a small group of patients to gather important safety and feasibility information.
People with NF1 often develop many cutaneous neurofibromas over time, which can be bothersome, disfiguring, or uncomfortable. Current treatment options are limited, so this trial is exploring whether this new virus-based treatment could offer a less invasive way to shrink or eliminate these tumors without surgery.
You likely qualify if…
You likely don't qualify if…
You will receive 8 injections of the medication over 4 months (2 injections in the first month, then 2 injections per month for 3 more months). Each injection is placed directly into the skin tumors. You will have screening visits to confirm you qualify, then regular visits for treatment and monitoring, with blood tests and photos or measurements of your tumors to track how they respond. After your final treatment, you will return for one follow-up visit 30 days later. The entire study participation will take approximately 5 months.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
United States